4.1 Article

Ethnic Differences in ATP-binding Cassette Transporter, Sub-family G, Member 2 (ABCG2/BCRP): Genotype Combinations and Estimated Functions

Journal

DRUG METABOLISM AND PHARMACOKINETICS
Volume 29, Issue 6, Pages 490-492

Publisher

JAPANESE SOC STUDY XENOBIOTICS
DOI: 10.2133/dmpk.DMPK-14-SC-041

Keywords

ABC transporters; urate excretion; gouty arthritis; single nucleotide polymorphism; nonsynonymous mutation

Funding

  1. Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan
  2. Ministry of Health, Labour and Welfare of Japan
  3. Ministry of Defense of Japan
  4. Japan Society for the Promotion of Science
  5. Takeda Science Foundation
  6. AstraZeneca VRI Research Grant
  7. Kawano Masanori Memorial Foundation for Promotion of Pediatrics
  8. Gout Research Foundation of Japan
  9. MEXT KAKENHI [221S0002, 25293145, 22689021, 25670307]
  10. Grants-in-Aid for Scientific Research [25670307, 22689021, 221S0002, 221S0001] Funding Source: KAKEN

Ask authors/readers for more resources

ATP-binding cassette transporter, sub-family G, member 2 (ABCG2/BCRP) is a xenobiotic transporter and also regulates serum uric acid levels as a urate transporter. We have shown that the severity of ABCG2 dysfunction can be estimated by simple genotyping of two dysfunctional variants, Q126X (rs72552713) and Q141K (rs2231142). This genotyping method is widely accepted for the risk analysis of hyperuricemia/gout, but there is no report on ethnic differences in ABCG2 dysfunctions. Here, we estimated ABCG2 dysfunctions by its genotype combination (Q126X and Q141K) and compared them in three different ethnic groups (500 Japanese, 200 Caucasians and 100 African-Americans). The minor allele frequencies of Q126X and Q141K in Japanese (0.025 and 0.275, respectively) were significantly higher than those in Caucasians (0.005 and 0.085, respectively) and African-Americans (0 and 0.090, respectively). Additionally, the rates of mild, moderate and severe ABCG2 dysfunctions in Japanese (35.4%, 12.4% and 1.6%, respectively) were higher than those in Caucasians (14.0%, 2.5% and 0%, respectively) and African-Americans (14.0%, 2.0% and 0%, respectively). Because ABCG2 dysfunctional diplotypes were commonly observed in both Caucasians (16.5%) and African-Americans (16.0%), the genotyping of the two ABCG2 dysfunctional variants is useful for evaluating individual differences in the ABCG2 dysfunction which affect the pharmacokinetics of substrate drugs and hyperuricemia risk in all three ethnic groups.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available